Science

Develops advanced biotech and high-tech products

Alameda, California, United States

About Science

Science.xyz develops specialized products and services in the biotech and high-tech sectors, focusing on areas like synthetic biology, stem cell research, microfabrication, and semiconductor devices. Their products are designed to meet the needs of clients such as academic institutions, research labs, and biotech companies. The company employs a skilled team of professionals, including scientists and engineers, to ensure their offerings are advanced and effective. Unlike many competitors, Science.xyz emphasizes collaboration and partnerships within the scientific community to enhance their product development. The goal of Science.xyz is to leverage scientific research to create valuable solutions that contribute to advancements in technology and biotechnology.

Alameda, CaliforniaHeadquarters

2021Year Founded

$25.3MTotal Funding

EARLY_VCCompany Stage

Consulting, Industrial & Manufacturing, BiotechnologyIndustries

201-500Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Flexible Vacation

Paid Parental Leave

Paid Sick Leave

401(k) Retirement Plan

Dependent Care Flexible Spending Account

Flexible Spending Account

Risks

Intellectual property disputes may arise from Pixium's PRIMA retinal implant acquisition.

New executive team integration may lead to strategic misalignments or transitional challenges.

Biohybrid neural interfaces face ethical and regulatory scrutiny, delaying market entry.

Differentiation

Science focuses on unmet medical needs with advanced biotech and high-tech solutions.

The company integrates bioelectronics with neural interfaces for vision restoration.

Science's strategic location in Alameda offers access to the thriving Bay Area tech market.

Upsides

Growing demand for wireless neural devices boosts Science's SciFi headstage and Synapse protocol.

Acquisition of Pixium's PRIMA implant aligns with bioelectronics and neural interface trends.

Experienced executives in financial and legal roles support strategic scaling and IP management.

Funding

Total raised$25.29 M

Latest valuation$130.00 M

StageEARLY_VC

EARLY VC

5/31/2024

$26

$130.00 M